Corrigendum to: JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure (Journal of Cardiac Failure, (2025), 31, 8, (1164-1322), (S1071916425001009), 10.1016/j.cardfail.2025.02.014)

In accordance with the proposal for JCS/JHFS 2025 guideline on diagnosis and treatment of heart failure from Japanese Association on Sarcopenia and Frailty and Japan Heart Rhythm Society, the authors corrected the tables as shown below. The gradient of the LVEF border has been changed from vertical to diagonal, the authors have replaced the Figure 8. 1) Page 1355, Table 9 (Corrected) References 1218a. Satake S, Arai H. Questionnaire for medical checkup of old-old (QMCOO). Geriatr Gerontol Int 2020; 20: 991 – 992. 1218b. Ishizaki T, Masui Y, Nakagawa T, Yoshida Y, Ishioka YL, Hori N, et al. Construct validity of a new health assessment questionnaire for the national screening program of older adults in Japan: The SONIC Study. Int J Environ Res Public Health 2022; 19: 10330. 2) Page 1316, the right column, line 21–22 and Page 1317, Recommendation Table (Recommendations and Levels of Evidence for Implantable Cardioverter Defibrillator Use in Primary Prevention of Sudden Cardiac Death in Heart Failure Patients) Incorrect: For non-ischemic HF patients meeting the same criteria, a Class IIa recommendation is given. Correct: For non-ischemic HF patients meeting the same criteria, a Class I or IIa recommendation is given depending on the presence or absence of NSVT, respectively, according to JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias.687a,687b,687c,719 References 687a. Sasaki S, Noda T, Okumura K, Nitta T, Aizawa Y, Ohe T, et al. Effectiveness of implantable cardioverter defibrillator in patients with non-ischemic heart failure with systolic dysfunction: Subanalysis of the Nippon Storm Study. Circ J 2022; 87: 92 – 100. 687b. Aonuma K, Ando K, Kusano K, Asai T, Inoue K, Inamura Y, et al.; HINODE Investigators. Primary results from the Japanese Heart Failure and Sudden Cardiac Death Prevention Trial (HINODE). ESC Heart Fail 2022; 9: 1584 – 1596. 687c. Kondo Y, Noda T, Takanashi Y, Sasaki S, Sato Y, Nitta T, et al. Two-year outcomes of primary prophylactic use of defibrillators for ischemic and non-ischemic cardiomyopathy: Propensity score-matched analysis from the Nippon Storm Study. Circ J 2024; 88: 1107 – 1114. 719. Nogami A, Kurita T, Abe H, Ando K, Ishikawa T, Imai K, et al. JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias. Circ J 2021; 85: 1104 – 1244. Recommendation Table (Corrected)Recommendations and Levels of Evidence for Implantable Cardioverter Defibrillator Use in Primary Prevention of Sudden Cardiac Death in Heart Failure PatientsRecommendationCORLOEIn HF patients with ischemic heart disease with NYHA Class II or higher and LVEF ≤35% who have been on appropriate GDMT for at least 3 months, ICD implantation is recommended to reduce mortality risk and for the primary prevention of SCD*.^610,682IAIn HF patients with non-ischemic heart disease with NYHA Class II or higher, LVEF ≤35%, and NSVT who have been on appropriate GDMT for at least 3 months, ICD implantation can be considered to reduce mortality risk and for the primary prevention of SCD.^{687a,687b,687c,719}IAIn HF patients with non-ischemic heart disease with NYHA Class II or higher and LVEF ≤35% who have been on appropriate GDMT for at least 3 months**, ICD implantation can be considered to reduce mortality risk and for the primary prevention of SCD.^{676,677,718,741,742}IIaAFor risk stratification of SCD in HF patients, the use of established scoring systems (e.g., MADIT-ICD Benefit Score or Seattle Proportional Hazard Score) and MRI studies can be considered.^743–745IIaB-NRICD implantation for primary prevention of SCD is not recommended in patients who meet the criteria for ICD placement but have end-stage HF, significant physical limitations from chronic conditions, or a life expectancy of <1 year.^679–681IIINo benefitC-LD *This excludes patients within 48 h of an acute myocardial infarction. **Without NSVT. COR, Class of Recommendation; GDMT, guideline-directed medical therapy; HF, heart failure; ICD, implantable cardioverter defibrillator; LOE, Level of Evidence; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; NYHA, New York Heart Association; SCD, sudden cardiac death.